1-10 of 10
Michael E. Jung
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 599: Combination of CDK4/6 inhibitors with biguanides for treatment of triple negative breast cancer

Mario Morales Martinez, Eduardo Mauricio Gonzalez, Gang Deng, Gaoyuan Ma, Hyunsoo Kim, Linsey Stiles, Nalo Hamilton, Michael E. Jung, Richard J. Pietras, Diana C. Marquez-Garban
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 599.
https://doi.org/10.1158/1538-7445.AM2024-599
Published: 22 March 2024
View article titled, Abstract 599: Combination of CDK4/6 inhibitors with biguanides for treatment of triple negative breast cancer
Journal Articles

Abstract 510: Targeting metabolic vulnerabilities to reduce triple negative breast cancer health disparities

Diana C. Márquez-Garban, Gang Deng, Lorena P. Burton, Gaoyuan Ma, Vishaka Muhunthan, Begonya Comin-Anduix, Gabriela Llarena, Neda Moatamed, Jennifer Murphy, Nalo Hamilton, Daivd Shackelford, Michael E. Jung, Richard J. Pietras
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 510.
https://doi.org/10.1158/1538-7445.AM2023-510
Published: 04 April 2023
View article titled, Abstract 510: Targeting metabolic vulnerabilities to reduce triple negative breast cancer health disparities
Journal Articles

Abstract 692: Discovery of novel metformin derivatives with potent antitumor activity in combination with immunotherapy for treatment of triple-negative breast cancer

Diana C. Márquez-Garban, Gang Deng, Begonya Comin-Anduix, Vishaka Muhunthan, Gaoyuan Ma, Jennifer Murphy, Alejandro J. Garcia, Cristian D. Yanes, Lorena R. Burton, Nalo Hamilton, David Shackelford, Michael E. Jung, Richard J. Pietras
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 692.
https://doi.org/10.1158/1538-7445.AM2020-692
Published: 15 August 2020
View article titled, Abstract 692: Discovery of novel metformin derivatives with potent antitumor activity in combination with immunotherapy for treatment of triple-negative breast cancer
Journal Articles

Abstract 1012: Selective estrogen receptor downregulators and immune checkpoint inhibitors in breast cancer immunotherapy

Diana C. Márquez-Garban, Gang Deng, Begonya Comin-Anduix, Alejandro J. Garcia, Emelyine Diers, Gaoyuan Ma, Nalo Hamilton, Michael E. Jung, Richard J. Pietras
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1012.
https://doi.org/10.1158/1538-7445.AM2019-1012
Published: 01 July 2019
View article titled, Abstract 1012: Selective estrogen receptor downregulators and immune checkpoint inhibitors in breast cancer immunotherapy
Journal Articles

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells

Yijiang Shi, Tracy R. Daniels-Wells, Patrick Frost, Jihye Lee, Richard S. Finn, Carolyne Bardeleben, Manuel L. Penichet, Michael E. Jung, Joseph Gera, Alan Lichtenstein
Journal: Cancer Research
Cancer Res (2016) 76 (19): 5822–5831.
https://doi.org/10.1158/0008-5472.CAN-16-1019
Published: 02 October 2016
View article titled, Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells
Open the PDF for Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells in another window
Includes: Supplementary data
Journal Articles

CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

Jemima Escamilla, Shiruyeh Schokrpur, Connie Liu, Saul J. Priceman, Diana Moughon, Ziyue Jiang, Frederic Pouliot, Clara Magyar, James L. Sung, Jingying Xu, Gang Deng, Brian L. West, Gideon Bollag, Yves Fradet, Louis Lacombe, Michael E. Jung, Jiaoti Huang, Lily Wu
Journal: Cancer Research
Cancer Res (2015) 75 (6): 950–962.
https://doi.org/10.1158/0008-5472.CAN-14-0992
Published: 12 March 2015
View article titled, CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy
Open the PDF for CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy in another window
Includes: Supplementary data
Journal Articles

Abstract C16: Targeting AR in castration-resistant prostate cancer: Development of ARN-509 and second-generation antiandrogen resistance models

James D. Joseph, Anna Aparicio, Josh Kaufman, Jackie Julien, Celine Bonnefous, Nicholas D. Smith, Peter Rix, Michael E. Jung, Charles L. Sawyers, Richard A. Heyman, Jeffrey H. Hager, Nicola J. Clegg, John Sensintaffar, Nhin Lu, Kate Grillot, Eric Bischoff, Gang Shao, Jing Qian, Beatrice Darimont
Journal: Cancer Research
Cancer Res (2012) 72 (4_Supplement): C16.
https://doi.org/10.1158/1538-7445.PRCA2012-C16
Published: 09 May 2013
View article titled, Abstract C16: Targeting AR in castration-resistant prostate cancer: Development of ARN-509 and second-generation antiandrogen resistance models
Journal Articles

An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity

Kevin J. Williams, Joseph P. Argus, Yue Zhu, Moses Q. Wilks, Beth N. Marbois, Autumn G. York, Yoko Kidani, Alexandra L. Pourzia, David Akhavan, Dominique N. Lisiero, Evangelia Komisopoulou, Amy H. Henkin, Horacio Soto, Brian T. Chamberlain, Laurent Vergnes, Michael E. Jung, Jorge Z. Torres, Linda M. Liau, Heather R. Christofk, Robert M. Prins, Paul S. Mischel, Karen Reue, Thomas G. Graeber, Steven J. Bensinger
Journal: Cancer Research
Cancer Res (2013) 73 (9): 2850–2862.
https://doi.org/10.1158/0008-5472.CAN-13-0382-T
Published: 30 April 2013
View article titled, An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity
Open the PDF for An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity in another window
Includes: Supplementary data
Journal Articles

Abstract 3491: Development of a new approach to kill non-small cell lung cancer cells with resistance to standard chemotherapy using parthenolide analogues

Diana C. Márquez-Garbán, Gang Deng, Hsiao-Wang Chen, Hermes J. Garbán, Michael E. Jung, Richard J. Pietras
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3491.
https://doi.org/10.1158/1538-7445.AM2012-3491
Published: 15 April 2012
View article titled, Abstract 3491: Development of a new approach to kill non-small cell lung cancer cells with resistance to standard chemotherapy using parthenolide analogues
Journal Articles

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

Nicola J. Clegg, John Wongvipat, James D. Joseph, Chris Tran, Samedy Ouk, Anna Dilhas, Yu Chen, Kate Grillot, Eric D. Bischoff, Ling Cai, Anna Aparicio, Steven Dorow, Vivek Arora, Gang Shao, Jing Qian, Hong Zhao, Guangbin Yang, Chunyan Cao, John Sensintaffar, Teresa Wasielewska, Mark R. Herbert, Celine Bonnefous, Beatrice Darimont, Howard I. Scher, Peter Smith-Jones, Mark Klang, Nicholas D. Smith, Elisa De Stanchina, Nian Wu, Ouathek Ouerfelli, Peter J. Rix, Richard A. Heyman, Michael E. Jung, Charles L. Sawyers, Jeffrey H. Hager
Journal: Cancer Research
Cancer Res (2012) 72 (6): 1494–1503.
https://doi.org/10.1158/0008-5472.CAN-11-3948
Published: 14 March 2012
View article titled, ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Open the PDF for ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment in another window
Includes: Supplementary data